Emcure Pharmaceuticals has entered into a distribution agreement with Roche for key products in the nephrology and transplant medicine portfolio. Effective April 1, 2026, Emcure will distribute Roche’s established brands like CellCept®, Mircera, and Neorecormon® across India. This strategic partnership aims to expand patient access to critical therapies for Chronic Kidney Disease (CKD) and improve anemia management outcomes nationwide.
Strategic Distribution Partnership Announced
Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) announced on March 2, 2026, that it has signed a distribution agreement with Roche for selected products within its nephrology and transplant medicine portfolio in India. This collaboration is set to become effective on April 1, 2026.
The primary goal of this agreement is to significantly expand patient access to essential critical therapies addressing Chronic Kidney Disease (CKD), anemia management, and transplant care throughout the country. Emcure will distribute Roche’s globally recognized brands, leveraging its strong domestic distribution network.
Key Products Included in the Agreement
The distribution mandate covers several important medications from Roche, including:
- CellCept®: Described as a globally leading immunosuppressant supporting organ transplants since 1995.
- Mircera and Neorecormon®: Proven therapies for anemia associated with CKD, notably featuring Mircera’s long-acting ESA administered once every 2–4 weeks.
Complementary Strengths and Market Vision
Emcure, noted as a market leader in anemia management, views Roche’s portfolio as a strong complement to its existing offerings in nephrology. Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, stated this partnership is a “natural extension” of Emcure’s commitment to improving outcomes in renal care.
Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets, expressed confidence in Emcure’s expertise and distribution capabilities, believing these medicines will reach a larger patient base benefiting from Roche’s innovations in transplant and CKD care.
About the Companies
Emcure Pharmaceuticals Ltd. (EPL) is headquartered in Pune and is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT October 2025. Roche Products (India) Private Limited is a wholly owned subsidiary of the Roche Group, the world’s largest biotech company.
Source: BSE
